Guidelines recommend glucagonlike peptide-1 receptor agonist (GLP-1RA) and/or sodium-glucose cotransporter 2 inhibitor (SGLT2i) as initial pharmacologic therapy in people with T2D and ASCVD or high risk for ASCVD, heart failure, or CKD for comprehensive cardiovascular (CV) and renal risk management; combination therapy with SGLT2i and GLP-1RA is recommended for this same population when glycemic targets have not been met with monotherapy [6, 7]. The gene discussed is SLC5A2; the disease is atherosclerosis.